Mark Scholz, MD
A board-certified medical oncologist, Mark C. Scholz, MD, serves as medical director of Prostate Oncology Specialists Inc. in Marina del Rey, CA, a medical practice exclusively focused on prostate cancer. He is also the executive director of the Prostate Cancer Research Institute He received his medical degree from Creighton University in Omaha, NE, Dr. Scholz completed his Internal Medicine internship and Medical Oncology fellowship at University of Southern California Medical Center.
Dr. Scholz is a strong advocate for patient empowerment. He is the co-author of the book Invasion of the Prostate Snatchers: No More Unnecessary Biopsies, Radical Treatment or Loss of Potency and has written and produced extensive educational material on the subject of prostate cancer in various medias which include DVDs, blogs, newsletters and pamphlets. He is frequently an invited guest speaker in the community at prostate cancer conferences and prostate cancer support groups throughout the world. He is also an educational speaker on behalf of Amgen, Dendreon and Sanofi-Aventis.
Dr. Scholz is also a past president and co-founder of the Prostate Cancer Research Institute (PCRI), a non-profit organization dedicated to patient education and research. PCRI clinical research on the topic of hormone therapy has been published in the Journal of Urology, The Prostate, and UROLOGY. The PCRI also provides financial support for research endeavors in the area of active surveillance, prostate imaging, and the development of new tumor markers. Future directions for PCRI research are aimed at enhancing the anticancer function of the immune system, developing treatments to prevent bone metastases, and evaluating the impact of nutritional supplements.
Dr. Scholz served as oncology director at the Memorial Campus of the Centinela Freeman Regional Medical Center from 1996-2001. His current hospital affiliations include St. John's Health Center, Marina del Rey Hospital, Los Angeles County Hospital and Motion Picture Hospital. His society memberships include the American Society of Clinical Oncology, American Society of Therapeutic Radiology, American Urologic Associate and European Associate of Urology. He continues as a primary investigator actively supervising a number of ongoing prostate cancer clinical trials and has authored or coauthored over 90 scholarly articles and abstracts in his area of expertise.